Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637212 | 0.85 | MAPT (0.45) | AGTR1AGTR2TLR7MAPTTLR8 | |
| SCHEMBL1206017 | 0.83 | AGTR1 (0.39) | AGTR1AGTR2TLR7MAPTTLR8 | |
| SCHEMBL1638689 | 0.82 | TLR7 (0.38) | TLR7TLR8POLB | |
| SCHEMBL1638607 | 0.80 | AGTR1 (0.39) | AGTR1AGTR2TLR7MAPTTLR8 | |
| SCHEMBL15509961 | 0.78 | MAPT (0.33) | AGTR1AGTR2MAPTPOLB | |
| SCHEMBL1637922 | 0.76 | CXCR4 (0.40) | — | |
| SCHEMBL1637920 | 0.74 | CXCR4 (0.63) | — | |
| SCHEMBL1638170 | 0.74 | MAPT (0.40) | AGTR1AGTR2TLR7MAPT | |
| SCHEMBL12762323 | 0.73 | CXCR4 (0.44) | — | |
| SCHEMBL1206862 | 0.72 | AGTR1 (0.41) | AGTR1AGTR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | AGTR1 1382/4885AGTR2 1282/4885TLR7 761/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | AGTR1 1110/4885AGTR2 1171/4885TLR7 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.